CytoGnomix has finalized our contract with Public Works Government Services Canada under the Build in Canada Innovation Program. This agreement licenses the Automated Dicentric Chromosome Identifier (ADCI) to the Consumer and Clinical Radiation Protection Bureau at Health Canada and Canadian Nuclear Laboratories and provides on-site training to these labs. These biodosimetry reference labs will test the software and provide feedback. Test results will support CytoGnomix’s submitted application to the Medical Device Bureau at Health Canada.
- April 18, 2017. US Patent 9,624,549 issued about chemotherapy target identification
- April 8, 2017. Presentation about chemotherapy outcome prediction
- March 31, 2017. New preprint on increased accuracy in radiation biodosimetry
- February 27, 2017. CytoGnomix finalizes contract with Government of Canada